3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Genitourinary
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Lymphoma, Large-Cell, Anaplastic
3
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Melanoma
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Interventions
fludarabine phosphate
7
pembrolizumab
6
Mycophenolic Acid
6
Peripheral Blood Stem Cell Transplantation
5
Nivolumab
5
Cyclosporine
5
Cyclophosphamide
5
Whole-Body Irradiation
4
Radiotherapy
3
Busulfan
3
Antilymphocyte Serum
3
temsirolimus
2
fludarabine
2
atezolizumab
2
alectinib
2
Tacrolimus
2
Sunitinib
2
Specimen Handling
2
Paclitaxel
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Dasatinib
2
Alemtuzumab
2
varlilumab
1
valspodar
1
utomilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
alectinib
×
Lymphoid
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts